NanoPass Technologies Expands Global Reach
NanoPass Technologies continues to strength its position in the healthcare realm by signing four distribution agreements, marking a significant expansion into new global markets. With these agreements, the company is reinforcing its commitment to precision, comfort, and control, particularly in the field of intradermal delivery.
New Distribution Paths for MicronJet™
With this recent development, NanoPass Technologies now operates in over 30 countries. The company has established an impressive network of 28 channels over the past year across several markets. This includes regions such as the United States, Canada, Italy, France, Spain, and the UK. This impressive growth trajectory underscores its mission to make the MicronJet™ the leading standard in intradermal delivery systems.
Integrated Solutions and Medical Applications
While the burgeoning aesthetics sector fuels initial growth, NanoPass is not just focused on immediate gains; the company is advancing its deep-tech mission in vital areas such as vaccines, local anesthesia, immunotherapy, and ocular treatments. This commitment to innovation paves the way for sustainable, almost pain-free medical delivery systems, courtesy of its proprietary MicronJet™ technology.
Advanced Delivery Technology
The MicronJet™ technology replaces traditional needles with delivery pyramids, which are under 1 mm long. Supported by more than 70 clinical studies and backed by regulatory approvals across critical markets such as the U.S. FDA, EU CE, Health Canada, and others, MicronJet™ assures safe and precise delivery of a wide range of aesthetic and therapeutic formulations.
Product Line Overview
NanoPass has developed a diverse product line, including the MicronJet™ 600 (0.6 mm), designed for skin rejuvenation, scar revision, hyperhidrosis, and local anesthesia. Their latest launch, the MicronJet™ 800 (0.8 mm), is specifically optimized for high-viscosity formulations and hair restoration treatments. This versatile range caters to various medical and aesthetic needs.
Leadership Thoughts on Growth
According to Daniel Levitats, CEO of NanoPass Technologies, this expansion marks a pivotal moment in the company’s evolution from a pioneering tech innovator to a dynamic global corporation. He stresses the ambition to position MicronJet™ as a universal benchmark for intradermal delivery across aesthetics and advanced therapeutics.
Tal Shlezinger, the company's VP of Sales & Marketing, also shared insights on the growing momentum from partners and clinicians worldwide. He highlighted that MicronJet™ effectively offers physicians an evidence-based solution that significantly enhances clinical outcomes while focusing on patient satisfaction.
Contact Information
For further inquiries, interested parties can reach out to NanoPass Technologies Ltd. through their noted media channels. The company's ongoing efforts in enhancing intradermal delivery solutions underscore their dedication to improving healthcare delivery and patient care.
Frequently Asked Questions
What is NanoPass Technologies known for?
NanoPass Technologies is recognized for its innovative MicronJet™ technology, specializing in intradermal delivery systems.
Where has NanoPass expanded its distribution?
The company has recently expanded its distribution into Singapore, Mexico, Colombia, and Australia.
What does the MicronJet™ technology replace traditional needles with?
The MicronJet™ technology utilizes silicon-crystal delivery pyramids, which are less than 1 mm in length.
What medical applications does NanoPass focus on?
NanoPass is involved in aesthetics, vaccines, local anesthesia, and immunotherapy.
How is the effectiveness of MicronJet™ validated?
MicronJet™ is backed by over 70 clinical studies and regulatory approvals from significant global health authorities.
